Literature DB >> 14508167

Procedure guidelines for radionuclide myocardial perfusion imaging.

C Anagnostopoulos1, M Harbinson, A Kelion, K Kundley, C Y Loong, A Notghi, E Reyes, W Tindale, S R Underwood.   

Abstract

Radionuclide myocardial perfusion imaging (MPI) is an established and non-invasive imaging technique with diagnostic and prognostic efficacy in the investigation of coronary artery disease. It is the only widely available test for assessing myocardial perfusion directly but there are variations in the way it is performed in different centres. Harmonization of practice, at least at a national level, is therefore essential, and clinical governance now makes it mandatory for practice to be based upon evidence whenever possible [ 1]. This is best achieved by expert analysis of the evidence and to this end the British Nuclear Cardiology Society (BNCS) in association with the British Cardiac Society (BCS) and the British Nuclear Medicine Society (BNMS) have developed procedure guidelines for tomographic myocardial perfusion imaging. A systematic literature search was performed and every effort was made to conform with the AGREE recommendations [ 2]. All recommendations are therefore based on either evidence from clinical studies, previous published guidelines or expert consensus of the writing and advisory groups. The guidelines cover the clinical indications of MPI, the methods used for stress testing, the radiopharmaceuticals and the injected activities and also issues related to acquisition, processing and interpretation of images. They do not cover the benefits or drawbacks of the technique in specific circumstances; neither do they address its cost effectiveness in clinical diagnosis and management nor its potential impact on clinical outcomes. The guidelines aim to assist medical practitioners and other health care professionals in recommending, performing, interpreting and reporting single photon emission computed tomography (SPECT) of myocardial perfusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508167     DOI: 10.1097/01.mnm.0000095842.16659.4d

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Improved compliance with reporting standards: A retrospective analysis of Intersocietal Accreditation Commission Nuclear Cardiology Laboratories.

Authors:  P Tim Maddux; Mary Beth Farrell; Joseph A Ewing; Peter L Tilkemeier
Journal:  J Nucl Cardiol       Date:  2016-11-09       Impact factor: 5.952

2.  Sixty-four-slice computed tomography coronary angiography compared with myocardial perfusion scintigraphy for the diagnosis of functionally significant coronary stenoses in patients with a low to intermediate likelihood of coronary artery disease.

Authors:  Edward D Nicol; James Stirrup; Eliana Reyes; Michael Roughton; Simon P G Padley; Michael B Rubens; S Richard Underwood
Journal:  J Nucl Cardiol       Date:  2008-04-16       Impact factor: 5.952

3.  Erythromycin as an alternative to reduce interfering extra-cardiac activity in myocardial perfusion imaging.

Authors:  M Vorster; M M Sathekge; P Rheeder
Journal:  Cardiovasc J Afr       Date:  2010 May-Jun       Impact factor: 1.167

4.  Do reconstruction filters really effect the volume and ejection fraction calculation with 99Tc-sestamibigated myocardial SPECT?

Authors:  Ora Manish; Subhash Chand Kheruka; Sukanta Barai; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2010-10

Review 5.  Diagnosing CAD: additional markers from myocardial perfusion SPECT.

Authors:  Guang-Uei Hung
Journal:  J Biomed Res       Date:  2013-09-30

6.  The additive prognostic value of coronary calcium score (CCS) to single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI)-real world data from a single center.

Authors:  Vinoda Sharma; Lal Mughal; Gerasimos Dimitropoulos; Awais Sheikh; Michael Griffin; Alexandra Moss; Alp Notghi; Manish Pandit; Derek L Connolly; Chetan Varma; Paulus Kirchhof
Journal:  J Nucl Cardiol       Date:  2019-12-03       Impact factor: 5.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.